Dr Reddy’s Laboratories

Dr. Reddy’s signs $131.6 million deal with Henlius to commercialize multiple myeloma biosimilar in US and Europe

Dr. Reddy’s Laboratories shares jump 3% after arm sells US manufacturing facility

Dr. Reddy’s Laboratories announces sale of Louisiana manufacturing facility and subsidiary

The sale aligns with Dr. Reddy’s strategic focus on optimizing its global operations. As stated by the company, the Shreveport facility has not been integral to its long-term product development pipeline.

Nifty 50 top gainers today on December 27: Dr. Reddy’s Laboratories, IndusInd Bank, Mahindra & Mahindra and more

Dr Reddy’s Laboratories shares fall over 2% as USFDA issues Form 483 with seven observations for Bollaram facility

Dr. Reddy’s Laboratories shares jump 2% as company clocks highest-ever revenue in Q2

Dr. Reddy’s Laboratories launches Elobixibat (BixiBat®) to treat chronic constipation in India

Dr. Reddy’s Laboratories subsidiary announces promising Phase 1 results for autologous CAR-T cell therapy

Dr Reddy’s Laboratories signs licensing deal with Gilead Sciences to manufacture Lenacapavir

Dr. Reddy’s Laboratories shares surge 2% following initiation of exclusive distribution agreement with Sanofi Healthcare India

Dr. Reddy’s Laboratories records strong Q3 earnings with blockbuster Cancer Drug Boost

Dr Reddy’s Laboratories Faces Share Price Dip 6% Amid FDA Observations

Dr. Reddy’s Laboratories fall 2% on the back of USFDA inspection findings

Dr Reddy stock dips nearly 1% on the back of antitrust litigation in US over cancer drug

Dr Reddy’s launches immunity-boosting gummies for children

Dr Reddy’s Laboratories on announced the launch of CeleHealth Kidz Immuno Plus Gummies in India.